Animal models of sepsis and its complications

被引：40
作者：
Fink, Mitchell P. [1 ,2 ,3 ,4 ]
机构：
[1] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15261 USA
[2] Log Therapeut Inc, Waltham, MA USA
[3] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA
来源：
KIDNEY INTERNATIONAL | 2008年 / 74卷 / 08期
关键词：
D O I：
10.1038/ki.2008.442
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Most currently used animal sepsis models fail to adequately replicate the clinical problem and, therefore, have only limited utility for investigating pathophysiological mechanisms or testing the efficacy of new therapeutic agents. Recent experimental findings support this view and suggest that models of acute infection in mice with pre-existing renal dysfunction may be useful in the development pathway for new therapeutic agents for sepsis.
引用
收藏
页码：991 / 993
页数：4
相关论文
共 17 条
  • [1] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    Angus, DC
    Linde-Zwirble, WT
    Lidicker, J
    Clermont, G
    Carcillo, J
    Pinsky, MR
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
  • [2] Bagshaw SM, 2008, CRIT CARE, V12, DOI [10.1186/cc6268, 10.1186/cc6863]
  • [3] Septic acute kidney injury in critically ill patients: Clinical characteristics and outcomes
    Bagshaw, Sean M.
    Uchino, Shigehiko
    Bellomo, Rinaldo
    Morimatsu, Hiroshi
    Morgera, Stanislao
    Schetz, Miet
    Tan, Ian
    Bouman, Catherine
    Macedo, Ettiene
    Gibney, Noel
    Tolwani, Ashita
    Oudemans-van Straaten, Heleen M.
    Ronco, Claudio
    Kellum, John A.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (03): : 431 - 439
  • [4] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [5] Challenge and rechallenge: Drotrecogin alfa (activated)-induced prolongation of activated partial thromboplastin time in a patient with severe sepsis
    Castelli, EE
    Culley, CM
    Fink, MR
    [J]. PHARMACOTHERAPY, 2005, 25 (08): : 1147 - 1150
  • [6] Drotrecogin alfa (activated) in severe sepsis: A systematic review and new cost-effectiveness analysis
    Costa V.
    Brophy J.M.
    [J]. BMC Anesthesiology, 7 (1)
  • [7] Pre-existing renal disease promotes sepsis-induced acute kidney injury and worsens outcome
    Doi, Kent
    Leelahavanichkul, Asada
    Hu, Xuzhen
    Sidransky, L.
    Zhou, Hua
    Qin, Yan
    Eisner, Christoph
    Schnermann, Juegen
    Yuen, Peter S. T.
    Star, Robert A.
    [J]. KIDNEY INTERNATIONAL, 2008, 74 (08) : 1017 - 1025
  • [8] Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study
    Kanji, Salmaan
    Perreault, Marc M.
    Chant, Clarence
    Williamson, David
    Burry, Lisa
    [J]. INTENSIVE CARE MEDICINE, 2007, 33 (03) : 517 - 523
  • [9] Understanding the inflammatory in pneumonia and sepsis - Results of the genetic and inflammatory markers of sepsis (GenIMS) study
    Kellum, John A.
    Kong, Lan
    Fink, Mitchell P.
    Weissfeld, Lisa A.
    Yealy, Donald M.
    Pinsky, Michael R.
    Fine, Jonathan
    Krichevsky, Alexander
    Delude, Russell L.
    Angus, Derek C.
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2007, 167 (15) : 1655 - 1663
  • [10] 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
    Levy, MM
    Fink, MP
    Marshall, JC
    Abraham, E
    Angus, D
    Cook, D
    Cohen, J
    Opal, SM
    Vincent, JL
    Ramsay, G
    [J]. CRITICAL CARE MEDICINE, 2003, 31 (04) : 1250 - 1256
12